|
Feb 18
|
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
|
|
Feb 18
|
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
|
|
Feb 7
|
Sanofi increases ownership stake partaking in pharma buyback trend
|
|
Feb 7
|
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
|
|
Feb 7
|
Press Release: Execution of a share buyback agreement for up to €2 billion
|
|
Feb 5
|
Sanofi (SNY): Among the Best Foreign Dividend Stocks to Invest In Now
|
|
Feb 5
|
Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call
|
|
Feb 4
|
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend
|
|
Feb 4
|
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
|
|
Feb 3
|
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
|
|
Feb 3
|
Sanofi kicks off share buyback plan with $3bn L’Oréal stake purchase
|
|
Feb 3
|
Sanofi’s Sarclisa combo approved in China for multiple myeloma
|
|
Feb 3
|
L’Oreal Sells €3 Billion of Sanofi Stock Back to Drugmaker
|
|
Feb 3
|
Press Release: Sanofi announces buy back of shares from L’Oréal
|
|
Jan 31
|
Sanofi reports Q4 2024 increase in net income to $916m
|
|
Jan 31
|
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
|
|
Jan 31
|
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
|
|
Jan 31
|
Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
|
|
Jan 31
|
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
|
|
Jan 30
|
Sanofi (SNY) Q4 2024 Earnings Call Transcript
|